s.agyeman97/100
Transit 6 days from stock held in Ireland against a quoted 6. Customs documentation correct at first presentation. Desiccant enclosed within the secondary container. Further submissions on later lots would improve coverage.
HJ — Hubei Jianxiang Bioscience Co., Ltd.
Xianning, CN · established 2015. The index holds 247 assay reports across 39 batches and 17 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where HJ sells
Hubei Jianxiang Bioscience Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit HJ at hubeijianxiang.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Hubei Jianxiang Bioscience Co., Ltd.
- Short code in this index
- HJ
- Also known as
- HJ · HJ Biotech · Hubei Jianxiang Bioscience
- Domain
- hubeijianxiang.net →
- City
- Xianning
- Region
- Xianning
- Country
- CN
- Established
- 2015
- First record in index
- 29 Apr 2024
- Most recent record
- 03 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
16.2%
n=247
Retail, shipped to the buyer
74.5%
n=247
Direct to the laboratory
3.2%
n=247
Median courier leg, direct despatch
7d
n=8
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 40 | 16.2% |
| Retail purchase, shipped to the buyer | 151 | 61.1% |
| Retail purchase via a third-party forwarder | 33 | 13.4% |
| Supplier despatch direct to the laboratory | 8 | 3.2% |
| Laboratory retained-sample archive | 15 | 6.1% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 247 HJ records the index holds, 40 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 13 of the 17 compounds HJ is represented by here — Tirzepatide, BPC-157, ARA-290, L-Glutathione (reduced), Ipamorelin, MK-677 (Ibutamoren mesylate) and 7 further compounds. Those are the HJ lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents HJ stock held in Ireland, with a transit of 6 working days against a quoted 6. Ireland is the only regional stock location named anywhere in HJ's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is HJ's own reviewers: 4 of the 26 on-record reviews state a quoted window and what happened against it. Where HJ despatched a sample direct to a laboratory, the courier leg ran a median 7 days across 8 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.09%
n=247
Interquartile range
0.99pp
n=247
10th percentile
98.24%
n=247
Pass rate vs index spec
95.5%
n=247
Median recovery vs claim
96.0%
n=136
Median water
4.74%
n=247
Median |mass error|
2.5ppm
n=204
Records carrying a flag
19.8%
n=247
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.66pp
n=31
Index median spread
0.67pp
n=28
Lots tested 3+ times
31
n=39
Across the 31 HJ lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.66 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.07pp
n=39
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
62%
n=39
Divergences beyond 1 pp
3%
n=39
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.09%
n=224
Supplier-supplied median
99.28%
n=8
Supplier-supplied share of records
3.2%
n=247
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of HJ batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
83/100
n=39
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 69% | 25 points | |
| Peptide content stated | 69% | 20 points | |
| Endotoxin stated | 41% | 15 points | |
| Named impurities rather than a total | 53% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 52 | 98.59 | 98.55 | +0.05 | 97.0 | 100 |
| BPC-157 | Tissue-repair | 33 | 99.39 | 99.16 | +0.23 | 98.0 | 100 |
| Semaglutide | Incretin | 31 | 99.16 | 98.89 | +0.27 | 97.0 | 100 |
| Ipamorelin | Growth-hormone | 21 | 99.16 | 99.47 | -0.31 | 99.0 | 62 |
| Retatrutide | Incretin | 16 | 98.11 | 98.37 | -0.27 | 96.5 | 100 |
| TB-500 | Tissue-repair | 15 | 99.66 | 99.53 | +0.13 | 98.5 | 100 |
| AOD-9604 | Metabolic | 15 | 98.78 | 99.29 | -0.51 | 98.0 | 100 |
| ARA-290 | Tissue-repair | 13 | 99.21 | 99.42 | -0.21 | 98.0 | 100 |
| L-Glutathione (reduced) | Short | 9 | 99.93 | 99.33 | +0.60 | 98.5 | 100 |
| PEG-MGF | Growth-hormone | 9 | 98.16 | 97.75 | +0.41 | 92.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 9 | 99.73 | 99.49 | +0.24 | 98.5 | 100 |
| Selank | Neuroactive | 7 n=7 | 99.30 | 99.59 | -0.29 | 99.0 | 100 |
| GHRP-6 | Growth-hormone | 5 n=5 | 99.37 | 99.54 | -0.17 | 99.0 | 80 |
| Epitalon | Short | 5 n=5 | 99.10 | 99.56 | -0.46 | 99.0 | 80 |
| GHRP-2 | Growth-hormone | 4 n=4 | 99.12 | 99.28 | -0.17 | 99.0 | 75 |
| IGF-1 LR3 | Growth-hormone | 2 n=2 | n<3 | 98.28 | — | 95.0 | 100 |
| GHK-Cu | Tissue-repair | 1 n=1 | n<3 | 98.56 | — | 97.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 1 | 14 | 99.54 | 99.13–99.93 | 2 |
| 2024-Q3 | 0 | 0 | n<3 | — | 0 |
| 2024-Q4 | 1 | 8 | 98.37 | 97.37–98.70 | 0 |
| 2025-Q1 | 6 | 37 | 98.71 | 98.01–99.93 | 11 |
| 2025-Q2 | 4 | 33 | 98.60 | 97.13–99.93 | 7 |
| 2025-Q3 | 8 | 44 | 99.25 | 97.65–99.93 | 9 |
| 2025-Q4 | 3 | 12 | 99.02 | 98.57–99.40 | 3 |
| 2026-Q1 | 5 | 29 | 99.20 | 98.23–99.93 | 3 |
| 2026-Q2 | 9 | 53 | 99.04 | 98.14–99.93 | 12 |
| 2026-Q3 | 2 | 17 | 99.21 | 98.69–99.93 | 2 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 118 | 99.14 | +0.00 | 99.14 |
| PeptideMeter | 35 | 98.90 | -0.05 | 98.95 |
| Medutest | 37 | 99.10 | +0.08 | 99.02 |
| VendorInvestigate | 22 | 99.08 | -0.11 | 99.19 |
| Nordanalyt | 23 | 99.05 | +0.02 | 99.03 |
| Kestrel | 12 | 99.49 | +0.24 | 99.25 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
94.0/ 100769 ratings across the index network
g.halvorsen96/100
Cross-check: Medutest and PeptideMeter, same lot, agreement to 0.1 points. Both agree with the declared figure.
o.silva99/100
Lot HJ-26-201 submitted to Janoshik. Declared 98.7%, reported 98.5%. Delta inside method repeatability. Independent verification of individual lots still required.
l.ostergaard98/100
Cold chain intact. Phase-change pack solid at arrival, day 3. Vial-to-vial mass variation under 2%. Documentation practice, not a single purity figure, is the substance here.
r.vermeulen98/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Reorder at 24 months within 0.1 points of the original. Not medical advice.
am.weiss97/100
Fill uniformity: 12 units weighed against declared fill, all within 2%. Medutest report held on file, figures match published.
re.sobczak95/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Desiccant enclosed within the secondary container.
i.vestergaard99/100
Batch record supplied in full on request, attached rather than summarised. Identifier matches across vial, certificate and commercial documentation.
e.nwosu99/100
Release signed and dated, named individual. Signature and release date present. Record covers the lots named. Not generalised.
ca.nyberg98/100
Retention time assigned to the principal peak, printed. Vial-to-vial mass variation under 2%.
is.beaulieu95/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Submitted to the index in full.
g.kjaer96/100
Consistency: 7 lots, purity band under 1.0 points wide. Janoshik report held on file, figures match published.
f.vukovic92/100
Residual-solvent screen included unrequested. No further comment.
mi.ibarra100/100
Water content on the first certificate with the titration method named. Regional stock held for the lines concerned. Record covers the lots named. Not generalised.
g.nilsen96/100
6 orders, 15 months. No substitution, no reformulation, no post-payment unavailability.
z.lindqvist97/100
Documentation complete at first issue. No supplementary request raised. Vial-to-vial mass variation under 2%.
f.stanescu99/100
Labelling printed, lot and date legible on every unit examined. Reorder at 20 months within 0.1 points of the original.
re.nilsen100/100
Quote returned with the correct vial size, unit price and lead time on the first pass. Documentation practice, not a single purity figure, is the substance here.
i.falk98/100
Supplementary certificate for a lot released 8 months earlier retrieved from supplier records on request. Peptide content 97.6%. Research use. Not approved for human administration.
i.ndiaye99/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Contributor declares no interest beyond the transaction.
a.bhattacharya96/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Technical response inside four hours, working day. Figures as reported by the named service. Not reproduced by the index.
sa.demir95/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Vial-to-vial mass variation under 2%. Subsequent orders placed with the same supplier.
y.bakken99/100
Direct-supply material 97.7%. Intermediary vial, same nominal description, 97.9%.
ka.salinas98/100
Repeat determination at 15 months: 97.5%. Original: 97.5%. No drift detected in this sample. No adverse observation.
ke.dahlberg97/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Peptide content 98.9%. Contributor declares no interest beyond the transaction.
na.ramos96/100
Peptide content reported separately from chromatographic purity across all 12 certificates held. Identifier matches across vial, certificate and commercial documentation.
Block 12
Most recent records
Block 13
Contributor annotations on HJ records 400
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on HJ material are below, each linked to the record it sits on.
Purity 99.50 %, water 3.55 %, counter-ion 9.74 % TFA, mass balance closed, provenance independent. There is nothing outstanding on this record.
Custody from checkout to injection is documented on this record. Provenance plus custody is what makes a single result generalise past the vial it came from.
Plate count on this run supports the separation claimed. A high purity figure from an inefficient column is a merged peak reported as a clean one; that is not what happened here.
Residual side-chain protection at +56 Da is the classic silent passenger on a high-purity trace. Nothing at that offset above threshold on this record.
The gradient is on the record, which is the first thing that should be true of any purity figure and often is not. 30 min at Janoshik puts this comparison on a documented footing.
A single result at 99.59 % is one draw. What makes a supplier's process legible is the spread across its lots, and that is on the scorecard rather than here. This record is one good point in a distribution worth reading whole.
Purity 99.03 %, water 3.37 %, counter-ion 6.28 % TFA, mass balance closed, provenance independent. There is nothing outstanding on this record.
For any sequence closed head-to-side-chain, the uncyclised precursor differs by 18 Da and is trivially separable by mass. The envelope on this record shows nothing at that offset.
Every annotation the index holds on HJ material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what HJ itself publishes, open hubeijianxiang.net → alongside.
Block 14
Where to buy HJ
Hubei Jianxiang Bioscience Co., Ltd. sells direct from hubeijianxiang.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the HJ store at hubeijianxiang.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.